<span item_type="fundamental" item_id="abb69aa9e0d1b5bf3e5ed624f7723440" counter_id="ST/US/RCKTW" env="prod"></span><span item_type="announcement" item_id="546906024872648193" env="prod"></span><p>EPS: As of FY2025 Q2, the actual value is USD -0.62.</p><p></p><h3>Segment Revenue</h3><ul><li>The company did not generate any revenue for the three and six months ended June 30, 2025, and 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1281895/000095017025104996/rckt-20250630.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Net Loss</strong>: The net loss for the three months ended June 30, 2025, was - $68.9 million, compared to - $69.6 million for the same period in 2024. For the six months ended June 30, 2025, the net loss was - $130.3 million, compared to - $131.7 million in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1281895/000095017025104996/rckt-20250630.htm"></span></li><li><strong>Research and Development Expenses</strong>: R&amp;D expenses decreased to $42.7 million for the three months ended June 30, 2025, from $46.3 million in 2024. For the six months ended June 30, 2025, R&amp;D expenses were $78.6 million, down from $91.6 million in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1281895/000095017025104996/rckt-20250630.htm"></span></li><li><strong>General and Administrative Expenses</strong>: G&amp;A expenses were $25.0 million for the three months ended June 30, 2025, down from $27.4 million in 2024. For the six months ended June 30, 2025, G&amp;A expenses increased to $53.5 million from $49.5 million in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1281895/000095017025104996/rckt-20250630.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Operating Cash Flow</strong>: Net cash used in operating activities was - $104.8 million for the six months ended June 30, 2025, compared to - $110.7 million in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1281895/000095017025104996/rckt-20250630.htm"></span></li><li><strong>Investing Cash Flow</strong>: Net cash used in investing activities was - $26.3 million for the six months ended June 30, 2025, compared to net cash provided by investing activities of $90.7 million in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1281895/000095017025104996/rckt-20250630.htm"></span></li><li><strong>Financing Cash Flow</strong>: Net cash provided by financing activities was $0.2 million for the six months ended June 30, 2025, compared to $2.7 million in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1281895/000095017025104996/rckt-20250630.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Stock-Based Compensation</strong>: Stock-based compensation expense was $21.2 million for the six months ended June 30, 2025, compared to $21.6 million in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1281895/000095017025104996/rckt-20250630.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: The company announced a strategic corporate reorganization in July 2025, focusing on the AAV cardiovascular platform and reprioritizing resources away from the FA and PKD programs. This restructuring is expected to reduce operating expenses by nearly 25% over the next 12 months.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1281895/000095017025104996/rckt-20250630.htm"></span></li><li><strong>Non-Core Business</strong>: The company is exploring external partnership options for the FA and PKD programs, indicating a shift in focus and resource allocation.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1281895/000095017025104996/rckt-20250630.htm"></span></li></ul>

ROCKET PHARMACEUTICALS INC C/WTS 02/09/2026 (TO PUR COM) | 10-Q: FY2025 Q2 EPS: USD -0.62